E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
breast cancer |
CARCINOMA MAMMARIO |
|
E.1.1.1 | Medical condition in easily understood language |
breast cancer |
CANCRO AL SENO |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Assess the impact of cryotherapy in reducing the incidence of onicopatie of moderate / severe intensity in addition to the 12 |
Valutare l¿impatto della crioterapia nella riduzione dell¿incidenza delle onicopatie di moderata/grave intensit¿ a completamento delle 12 somministrazioni settimanali di paclitaxel. |
|
E.2.2 | Secondary objectives of the trial |
1) evaluate the "time to the appearance" of each of onicopatie degree calculated in number of days from the start of therapy; 2) assess the tolerance and patient compliance through the intervention of cryotherapy satisfaction scale to 2 items (satisfied, not satisfied).
|
1) valutare il ¿tempo alla comparsa¿ delle onicopatie di ogni grado calcolato in numero di giorni dall¿inizio della terapia; 2) valutare la tolleranza e la compliance delle pazienti all¿intervento di crioterapia attraverso scala di soddisfazione a 2 items (soddisfatto, non soddisfatto). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Patients with breast cancer and undergoing adjuvant therapy with weekly paclitaxel (80 to 100 mg / m) for at least 12 weeks; 2) Collaboration and written informed consent to treatment |
1)Pazienti affette da carcinoma mammario e sottoposte a terapia adiuvante con paclitaxel settimanale (da 80 a 100 mg/mq) per almeno 12 settimane; 2)Collaborazione al trattamento e consenso informato scritto |
|
E.4 | Principal exclusion criteria |
1) Previous nail diseases; 2) Syndrome Raynoud; 3) Prior treatment with taxanes; 4) no treatment compliance or lack of cooperation |
1) Precedenti patologie ungueali; 2) Sindrome di Raynoud; 3) Precedenti trattamenti con taxani; 4) Non compliance al trattamento o scarsa collaborazione. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentuale di pazienti con onicopatie G2-G3 (sec CTCAE v 4.03) valutate a completamento delle 12 somministrazioni settimanali di paclitaxel |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Tempo alla comparsa di onicopatia (calcolato dalla prima somministrazione del paclitaxel, in giorni). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |